NEW YORK (GenomeWeb News) - Rosetta Genomics said today it has licensed PCR technology from Roche Molecular Diagnostics for use in its microRNA-based diagnostic tests.
The company plans to use the PCR technology in its efforts to identify microRNA biomarkers in several different sample types and body fluids.
Rosetta Genomics a month ago struck a license agreement with Nanogen for its MGB Probe technology, which it also plans to use in the development of its line of diagnostic tests.
Rosetta has said that in 2008 it plans to launch diagnostic tests for squamous and non-squamous lung cancers, for mesothelioma and lung adenocarcinoma, and to identify the origin of tumors.
Financial terms of the agreement were not released.